Clarius Group LLC Trims Stock Position in Amgen Inc. (NASDAQ:AMGN)

Clarius Group LLC cut its position in Amgen Inc. (NASDAQ:AMGN) by 1.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 8,280 shares of the medical research company’s stock after selling 131 shares during the quarter. Clarius Group LLC’s holdings in Amgen were worth $2,663,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Boone Capital Management LLC increased its stake in Amgen by 3.4% in the 4th quarter. Boone Capital Management LLC now owns 101,508 shares of the medical research company’s stock worth $29,236,000 after purchasing an additional 3,382 shares during the period. Bontempo Ohly Capital Mgmt LLC increased its holdings in shares of Amgen by 0.8% during the fourth quarter. Bontempo Ohly Capital Mgmt LLC now owns 8,506 shares of the medical research company’s stock valued at $2,450,000 after acquiring an additional 67 shares in the last quarter. Gotham Asset Management LLC raised its holdings in Amgen by 28.4% in the 4th quarter. Gotham Asset Management LLC now owns 41,390 shares of the medical research company’s stock worth $11,921,000 after acquiring an additional 9,164 shares during the last quarter. Groupama Asset Managment purchased a new stake in shares of Amgen during the fourth quarter valued at $10,955,000. Finally, Grayhawk Investment Strategies Inc. bought a new stake in shares of Amgen in the fourth quarter worth approximately $454,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.1 %

Amgen stock opened at $320.68 on Friday. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a market cap of $172.31 billion, a PE ratio of 55.25, a PEG ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The business’s 50-day simple moving average is $326.17 and its two-hundred day simple moving average is $310.22.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The company had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.00 EPS. Equities analysts anticipate that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.81%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is presently 154.91%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. TD Cowen upped their price objective on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Morgan Stanley reduced their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a report on Thursday, July 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $326.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.